Anti-C5 as prophylactic therapy in atypical hemolytic uremic syndrome in living-related kidney transplantation

Transplantation

Volumn 96, Issue 4, 2013, Pages

  Pelicano, Miquel Blasco ^a   De Córdoba, Santiago Rodríguez ^b   Diekmann, Fritz ^a   Saiz, Mercedes ^c   Herrero, Sara ^a   Oppenheimer, Federic ^a   Campistol, Josep M ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

^b CENTRO DE INVESTIGACIONES BIOLÓGICAS   (Spain)

^c HOSPITAL CAN MISSES   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENT COMPONENT C3; COMPLEMENT COMPONENT C5; COMPLEMENT FACTOR H; CREATININE; ECULIZUMAB; HAPTOGLOBIN; LACTATE DEHYDROGENASE; MENINGOCOCCUS VACCINE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RAPAMYCIN; STEROID; THYMOCYTE ANTIBODY;

ADULT; ALLELE; CARBOXY TERMINAL SEQUENCE; CASE REPORT; DRUG DOSE INCREASE; FEMALE; GENETIC RISK; HAPLOTYPE; HEMODIALYSIS; HEMOLYTIC UREMIC SYNDROME; HOMOZYGOSITY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFECTION PREVENTION; KIDNEY DISEASE; KIDNEY TRANSPLANTATION; LETTER; LIVING DONOR; MENINGOCOCCOSIS; MUTATIONAL ANALYSIS; PRIORITY JOURNAL; PROPHYLAXIS; THROMBOCYTE COUNT; URINE VOLUME; VACCINATION;

ANTIBODIES, MONOCLONAL, HUMANIZED; COMPLEMENT C5; COMPLEMENT FACTOR H; COMPLEMENT INACTIVATING AGENTS; FEMALE; HEMOLYTIC-UREMIC SYNDROME; HUMANS; KIDNEY FAILURE, CHRONIC; KIDNEY TRANSPLANTATION; LIVING DONORS; MUTATION, MISSENSE; YOUNG ADULT;

EID: 84883374274     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e31829d388d     Document Type: Letter

References (17)

1. Noris M, Remuzzi G. Hemolytic uremic syndrome. J Am Soc Nephrol 2005; 16: 1035.
2. Bresin E, Daina E, Norris M, et al. Outcome of renal transplantation in patients with non-Shiga toxin-associated hemolytic uremic syndrome: Prognostic significance of genetic background. Clin J Am Soc Nephrol 2006; 1: 88.
3. Zuber J, Le Quintrec M, Krid S, et al. Eculizumab for atypical hemolytic uremic syndrome recurrence in renal transplantation. Am J Transplant 2012; doi 10.1111/j.1600-6143.2012.04252.x.
4. Noris M, Remuzzi G. Atypical hemolyticuremic syndrome. N Engl J Med 2009; 361: 1676.
5. Zuber J, Le Quintrec M, Sberro-Soussan R, et al. New insights into post-renal transplant hemolytic uremic syndrome. Nat Rev Nephrol 2011; 7: 23.
6. Loirat C, Fremeaux-Bacchi V. Hemolytic uremic syndrome recurrence after renal transplantation. Pediatr Transplant 2008; 12: 619.
7. Donne RL, Abbs I, Barany P, et al. Recurrence of hemolytic uremic syndrome after live related renal transplantation associated with subsequent de novo disease in the donor. Am J Kidney Dis 2002; 40: E22.
8. Saland JM, Ruggenenti P, Remuzzi G. Liver-kidney transplantation to cure atypical haemolytic uremic syndrome. J Am Soc Nephrol 2009; 20: 940.
9. Legendre CM, Licht C, Muus P, et al. Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome. N Engl J Med 2013; 368: 2169.
10. Nester C, Stewart Z, Myers D, et al. Preemptive eculizumab and plasmapheresis for renal transplant in atypical haemolytic uremic syndrome. Clin JAmSocNephrol 2011; 6: 1488.
11. Zimmerhackl LB, Le Quintrec M, Krid S, et al. Prophylactic eculizumab after renal transplantation in atypical hemolytic-uremic syndrome. N Engl JMed 2010; 362: 18.
12. Weitz M, Ammon O, Bassler D, et al. Prophylactic eculizumab prior to kidney transplantation for atypical hemolytic uremic syndrome. Pediatr Nephrol 2011; 26: 1325.
13. Krid S, Roumenina LT, Beury C, et al. Renal transplantation under prophylactic eculizumab in atypical hemolytic uremic syndrome with CFH/CFHR1 hybrid protein. Am J Transplant 2012; 12: 1938.
14. English J, Evan A, Houghton DC, et al. Cyclosporine-induced acute renal dysfunction in the rat. Evidence of arteriolar vasoconstriction with preservation of tubular function. Transplantation 1987; 44: 135.
15. Ramzy D, Rao V, Tumiati LC, et al. Role of endothelin-1 and nitric oxide bioavailability in transplant-related vascular injury: Comparative effects of rapamycin and cyclosporine. Circulation 2006; 114: I214.
16. Ponticelli C. De novo thrombotic microangiopathy. An underrated complication of renal transplantation. Clin Nephrol 2007; 67: 335.
17. Burdmann EA, Andoh TF, Yu L, et al. Cyclosporine nephrotoxicity. Semin Nephrol 2003; 23: 465.